Speaker Emily Fridlington, MD
Program Learning Objectives:
Upon successful completion...

Speaker Emily Fridlington, MD
Program Learning Objectives:
Upon successful completion...
JDNA - The Official Journal of the Dermatology Nurses' Association -…
The Dermatology Nurse’s Association (DNA) supports the recommendation that the FDA include Alopecia Areata (AA) as a priority for research in the patient-focused drug development initiative being conducted as part of the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). Alopecia Areata affects approximately two percent of the population overall, including more than 5 million people in the United States alone (National Alopecia Areata Foundation). Read the full letter to the FDA here.
Launched in 2009, the Journal of the Dermatology Nurses' Association (JDNA) is owned solely by the DNA and published by Lippincott, Williams, and Wilkins (LWW).
Dermatology Nurses' Association | 15000 Commerce Parkway, Suite C Mount Laurel, NJ 08054
Phone: 800-454-4362 | Fax: 856-439-0525 | Email: dna@dnanurse.org
Copyright ©2011 Dermatology Nurses' Association (DNA). Sitemap | Privacy Policy
No materials, including graphics, may be reused, modified, or reproduced without written permission.
DNA is professionally managed by Association Headquarters